LEXINGTON, Mass. – November 15, 2016 (BUSINESS WIRE) -- MC10, Inc., a company developing innovative solutions for the advancement of physiological research and healthcare, today announced the appointment of Keith A. Katkin to the company’s Board of Directors.
“The expertise of the MC10 Board has grown tremendously over the past year. Keith Katkin’s history of leadership in the pharmaceutical space, and his ability to steer his companies to financial success, will further strengthen the MC10 team and our goal of reshaping healthcare,” commented Scott Pomerantz, MC10’s Chief Executive Officer, President and executive member of the Board of Directors.
Mr. Katkin served as the president and Chief Executive Officer of Avanir Pharmaceuticals from 2007 through the company’s acquisition by Otsuka pharmaceuticals in 2015. Avanir Pharmaceuticals focused on the development, acquisition, and commercialization of therapeutic products for the treatment of central nervous system disorders. Mr. Katkin was appointed by the company’s Board of Directors to lead Avanir through turnaround and restructuring, and his successful implementation of a new corporate strategy increased market capitalization from $50 million to $3.5 billion and grew the team from 17 employees to over 500.
Prior to serving as President and CEO, Mr. Katkin led all sales, marketing, and medical affairs at Avanir as the Senior Vice President of Sales and Marketing. Mr. Katkin was the Vice President of Commercial and Business Development at the privately owned Peninsula Pharmaceuticals from 2004 to 2005 and the Vice President of Marketing at Intermune, a publicly traded biotechnology company, from 2002 to 2004. He previously held several titles at Amgen and Abbott Laboratories.
“MC10’s technology has the potential to truly impact the healthcare space, and most importantly, to one day improve the overall quality of care. I look forward to serving on the Board of Directors, and to contributing as the company continues to grow and develop innovative solutions for patients and providers.” stated Mr. Katkin.
Mr. Katkin currently serves on the Board of Directors of Avanir Pharmaceuticals, Carbylan Therapeutics, Brain Injury Association of America, CoverMyMeds, Otic Pharmaceuticals, and Rigel Pharmaceuticals. Mr. Katkin earned his Bachelor of Science in Business from Indiana University and his Masters of Business Administration from the Anderson School of Management.
About MC10, Inc.
MC10 is a private company, backed by a strong syndicate of financial and strategic investors, that is improving human health through digital healthcare solutions. The company combines its proprietary ultra-thin, flexible body-worn sensors with advanced analytics to unlock health insights from physiological data. MC10 has received widespread recognition for its revolutionary technology and was recently named in Fast Company’s Most Innovative Companies in 2016 as a leader in healthcare. MC10 is headquartered in Lexington, MA. Visit MC10 online at www.mc10inc.com.
MC10® and the MC10 logo are registered marks owned by MC10, Inc.